Powder: -20°C for 3 years | In solvent: -80°C for 1 year
HBX 19818 is a specific ubiquitin-specific protease 7 (USP7) inhibitor (IC50: 28.1 μM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 54.00 | |
2 mg | In stock | $ 79.00 | |
5 mg | In stock | $ 128.00 | |
10 mg | In stock | $ 198.00 | |
25 mg | In stock | $ 347.00 | |
50 mg | In stock | $ 515.00 | |
100 mg | In stock | $ 747.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 143.00 |
Description | HBX 19818 is a specific ubiquitin-specific protease 7 (USP7) inhibitor (IC50: 28.1 μM). |
Targets&IC50 | USP7:28.1 μM |
In vitro | HBX 19818 inhibits HCT116 proliferation in a dose-dependent manner (IC50: ~2 μM). HBX 19818 selectively inhibits USP7 (IC50: ~6 μM in human cancer cells). HBX 19818 (1.5, 4, 12, 36, or 100 μM) inhibits USP7 deubiquitination of polyubiquitinated p53. HBX 19818 displays no effects on USP8, USP5, USP10, CYLD, UCH-L1, UCH-L3, or on SENP1, a SUMO protease (IC50s of > 200 μM). HBX 19818 (30 μM) also causes significantly higher levels of Mdm2 polyubiquitinated forms in USP7-overproducing HEK293 cells than those in DMSO-treated control cells. |
Molecular Weight | 421.96 |
Formula | C25H28ClN3O |
CAS No. | 1426944-49-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 20 mg/mL (47.40 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
HBX 19818 1426944-49-1 Cell Cycle/Checkpoint DNA Damage/DNA Repair Ubiquitination DUB HBX19818 Deubiquitinase Inhibitor DUBs inhibit HBX-19818 inhibitor